Researchers say GlycoCaging may offer a route to rescue promising drug candidates that currently show unacceptable systemic ...

A new approach to drug design can deliver medicine directly to the gut in mice at significantly lower doses than current inflammatory bowel disease treatments.

Cash balance of approximately $60.9 million as of March 31, 2025, expected to fund operations into 2027 – AUSTIN, TX and DURHAM, NC, May 01, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) ...

High cannabis use prior to a colorectal cancer (CRC) diagnosis was associated with an increased risk of CRC mortality in an ...

Researchers and clinicians have developed major new guidelines for the monitoring of patients with inflammatory bowel disease ...

Recent years have seen significant advancements in UC treatment, offering renewed hope for patients seeking effective and ...

Background IBD is a chronic inflammatory condition driven by complex genetic and immune interactions, yet preclinical models ...

Immunic's lead asset, vidofludimus calcium, shows promise in MS trials, with positive interim results. See why I rate IMUX ...

The risk of developing blood cancer increases with age. The finding that a molecule from gut bacteria plays a part points to ...

In these videos, Sushila Dulal, MD, associate professor of medicine at the University Chicago of Medicine, discusses the latest treatments, state of the pipeline and unmet needs for patients with ...

Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost ...